Valuing vaccines using value of statistical life measures.

Area of Science:

• Health economics
• Vaccine evaluation
• Public health policy

Background:

• Vaccines are crucial for public health, but resource limitations necessitate rigorous evaluation of investments.
• Standard economic assessments like cost-effectiveness analysis may underestimate the full benefits of vaccinations.
• Childhood immunizations impact health, productivity, and economic well-being through various channels.

Purpose of the Study:

• To compare benefit-cost analysis (BCA) and cost-effectiveness analysis (CEA) for evaluating vaccine interventions.
• To explore the use of willingness-to-pay (WTP) measures within BCA to capture non-health benefits.
• To address concerns about equity and discrimination against the poor in WTP methodologies.

Main Methods:

• Review and comparison of BCA and CEA methodologies.
• Discussion of willingness-to-pay (WTP) measures, including the value of a statistical life (VSL).
• Examination of income-sensitive distributional weights to ensure equity in WTP.

Main Results:

• Standard CEA, using metrics like QALYs and DALYs, may significantly underestimate vaccine benefits.
• BCA, incorporating WTP, can quantify non-health benefits such as productivity and economic well-being.
• WTP methods, when adjusted for income distribution, are not discriminatory against the poor.

Conclusions:

• Willingness-to-pay methods offer a more comprehensive assessment of vaccine value by including non-health economic benefits.
• Appropriate application of WTP can ensure equitable valuation of health interventions across different income groups.
• These methods provide crucial insights for prioritizing vaccine investments effectively.